IPSEN AND TERCICA TO ENTER INTO WORLDWIDE STRATEGIC COLLABORATION IN ENDOCRINOLOGY

Ipsen and Tercica announced that they have agreed to a worldwide strategic collaboration in endocrinology. In cross licensing agreements, Ipsen will grant to Tercica exclusive rights to sell Somatuline Autogel, a leading product in the European acromegaly market, in the United States and Canada. Tercica will grant to Ipsen exclusive rights to sell Increlex, a leading product in the United States for the treatment of short stature associated with severe Primary IGF-1 deficiency (Primary IGFD), in all regions of the world except the United States, Japan, Canada, the Middle East and Taiwan. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=3397461)